Strategies for Improving Hepatitis C Treatment Access in the United States: State Officials Address High Drug Prices, Stigma, and Building Treatment Capacity Academic Article uri icon

Overview

MeSH Major

  • Antiviral Agents
  • HIV Infections
  • Hepatitis C
  • Ribavirin
  • Sofosbuvir

abstract

  • While treatment eligibility criteria for HCV treatment are improving, many other barriers remain to achieving the scale-up needed to end the epidemic. Political disinterest, stigma, and a lack of specialty providers are continued barriers in some jurisdictions. States may need to invest in strategies to overcome these barriers, such as engaging in public and provider education and ensuring that treatment by primary care providers is reimbursed. Despite uncertainty about how federal policy changes to Medicaid may affect states' ability to respond, states can identify opportunities to improve access.

publication date

  • May 2019

Research

keywords

  • Academic Article

Identity

Language

  • eng

PubMed Central ID

  • PMC6309344

Digital Object Identifier (DOI)

  • 10.1097/PHH.0000000000000829

PubMed ID

  • 29927900

Additional Document Info

start page

  • 245

end page

  • 252

volume

  • 25

number

  • 3